Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - CAPRICOR THERAPEUTICS, INC. | tv481172_ex10-1.htm |
| 8-K - FORM 8-K - CAPRICOR THERAPEUTICS, INC. | tv481172_8k.htm |
Exhibit 99.1
| CAPRICOR THERAPEUTICS, INC. |
| CONDENSED CONSOLIDATED BALANCE SHEETS |
| (UNAUDITED) |
| ASSETS | ||||||||||||
| September 30, 2017 | Pro-Forma Adjustments (1) | Pro-Forma September 30, 2017 | ||||||||||
| CURRENT ASSETS | ||||||||||||
| Cash and cash equivalents | $ | 8,897,087 | $ | 8,897,087 | ||||||||
| Marketable securities | 4,997,850 | 4,997,850 | ||||||||||
| Restricted cash | 610,175 | 610,175 | ||||||||||
| Grant receivable | 537,030 | 537,030 | ||||||||||
| Prepaid expenses and other current assets | 190,278 | 190,278 | ||||||||||
| TOTAL CURRENT ASSETS | 15,232,420 | 15,232,420 | ||||||||||
| PROPERTY AND EQUIPMENT, net | 394,031 | 394,031 | ||||||||||
| OTHER ASSETS | ||||||||||||
| Intangible assets, net of accumulated amortization of $183,990 at September 30, 2017 | 105,692 | 105,692 | ||||||||||
| Other assets | 61,396 | 61,396 | ||||||||||
| TOTAL ASSETS | $ | 15,793,539 | $ | 15,793,539 | ||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||
| CURRENT LIABILITIES | ||||||||||||
| Accounts payable and accrued expenses | $ | 1,264,325 | $ | 1,264,325 | ||||||||
| Accounts payable and accrued expenses, related party | 99,903 | 99,903 | ||||||||||
| Loan payable, current | 14,155,857 | (14,155,857 | ) | - | ||||||||
| Accrued interest, current | 1,167,969 | (1,167,969 | ) | - | ||||||||
| TOTAL CURRENT LIABILITIES | 16,688,054 | (15,323,826 | ) | 1,364,228 | ||||||||
| LONG-TERM LIABILITIES | ||||||||||||
| CIRM liability | 3,376,259 | 3,376,259 | ||||||||||
| TOTAL LONG-TERM LIABILITIES | 3,376,259 | 3,376,259 | ||||||||||
| TOTAL LIABILITIES | 20,064,313 | 4,740,487 | ||||||||||
| COMMITMENTS AND CONTINGENCIES (NOTE 7) | ||||||||||||
| STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding | - | - | ||||||||||
| Common stock, $0.001 par value, 50,000,000 shares authorized, 25,100,388 issued and outstanding at September 30, 2017 | 25,100 | 25,100 | ||||||||||
| Additional paid-in capital | 59,548,523 | 59,548,523 | ||||||||||
| Accumulated other comprehensive income | 8,593 | 8,593 | ||||||||||
| Accumulated deficit | (63,852,990 | ) | 15,323,826 | (48,529,164 | ) | |||||||
| TOTAL STOCKHOLDERS' EQUITY (DEFICIT) | (4,270,774 | ) | 15,323,826 | 11,053,052 | ||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ | 15,793,539 | $ | 15,793,539 | ||||||||
(1) To reflect the forgiveness of the CIRM Loan Balance. This is comprised of $14,405,857 of principal plus accrued interest. $250,000 of such principal will be recorded subsequent to September 30, 2017. As such, the pro-forma adjustments only include the balance as of September 30, 2017.